SATELLOS BIOSCIENCE INC (MSCL.CA) Stock Price, Forecast & Analysis
TSX-V:MSCL • CA45107J1057
MSCL.CA Key Statistics, Chart & Performance
The current stock price of MSCL.CA is 16.32 CAD. In the past month the price increased by 11.48%. In the past year, price increased by 54.55%.
MSCL.CA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MSCL.CA. When comparing the yearly performance of all stocks, MSCL.CA is one of the better performing stocks in the market, outperforming 81.2% of all stocks.
MSCL.CA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MSCL.CA Forecast & Estimates
MSCL.CA Ownership
MSCL.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 573.937M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 406.658M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 151.996M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 74.235M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.18 | 50.268M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 38.57M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.94 | 33.252M | ||
| RVX | RESVERLOGIX CORP | N/A | 33.069M | ||
| HEM | HEMOSTEMIX INC | N/A | 16.596M | ||
| MPH | MEDICURE INC | N/A | 9.918M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About MSCL.CA
Company Profile
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario and currently employs 3 full-time employees. The company went IPO on 2006-12-01. The firm is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.
Company Info
SATELLOS BIOSCIENCE INC
79 Wellington Street West, 33rd Floor
TORONTO ONTARIO CA
Employees: 3
Phone: 16476601780
SATELLOS BIOSCIENCE INC / MSCL.CA FAQ
What does SATELLOS BIOSCIENCE INC do?
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario and currently employs 3 full-time employees. The company went IPO on 2006-12-01. The firm is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.
Can you provide the latest stock price for SATELLOS BIOSCIENCE INC?
The current stock price of MSCL.CA is 16.32 CAD. The price increased by 0.93% in the last trading session.
Does SATELLOS BIOSCIENCE INC pay dividends?
MSCL.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MSCL stock?
MSCL.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the number of employees for SATELLOS BIOSCIENCE INC?
SATELLOS BIOSCIENCE INC (MSCL.CA) currently has 3 employees.
Who owns SATELLOS BIOSCIENCE INC?
You can find the ownership structure of SATELLOS BIOSCIENCE INC (MSCL.CA) on the Ownership tab.